NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)
Authors
McNamara, Mairead GGoyal, L.
Doherty, M.
Springfeld, C.
Cosgrove, D.
Sjoquist, K. M.
Park, J. O.
Verdaguer, H.
Braconi, C.
Ross, P. J.
Gramont, A.
Zalcberg, J. R.
Palmer, D. H.
Valle, Juan W
Knox, J. J.
Affiliation
Division of Cancer Sciences, The University of Manchester & The Christie NHS Foundation Trust, Manchester,Issue Date
2020
Metadata
Show full item recordAbstract
Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal of NUC-1031/cisplatin in the Phase Ib ABC-08 study suggested that this combination may represent a more efficacious therapy than gemcitabine/cisplatin for patients with aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients /=18 years with untreated histologically/cytologically-confirmed aBTC (including cholangiocarcinomaCitation
M. G. McNamara, L. Goyal, M. Doherty et al. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncol. 2020;16(16):1069-1081.Journal
Future OncologyDOI
10.2217/fon-2020-0247PubMed ID
32374623Additional Links
https://dx.doi.org/10.2217/fon-2020-0247Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.2217/fon-2020-0247
Scopus Count
Collections
Related articles
- A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
- Authors: McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, Ryder WD, Barber S, Gnanaranjan C, Ghazaly E, Evans TRJ, Valle JW
- Issue date: 2021 Apr
- NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
- Authors: Kapacee ZA, Knox JJ, Palmer D, Blagden SP, Lamarca A, Valle JW, McNamara MG
- Issue date: 2020 Jun 11
- Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
- Authors: Abdel-Rahman O, Elsayed Z, Elhalawani H
- Issue date: 2018 Apr 6
- A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
- Authors: Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW
- Issue date: 2016 Feb 24
- Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
- Authors: Perkhofer L, Berger AW, Beutel AK, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Goetze TO, Muche R, Seufferlein T, Ettrich TJ
- Issue date: 2019 Oct 23